Andrew Allen

Andrew R.
Allen was the founder of Nexoplex Bio, Inc., founded in 2015, serving as Director from 2024 to 2025.
Dr. Allen is the founder of Clovis Oncology, Inc., founded in 2009, serving as Chief Medical Officer & EVP-Clinical Development from 2011 to 2015.
Dr. Allen is also the founder of Revitope Oncology, Inc...
Dr. Allen is currently Chairman at Peptone Ltd. since 2023.
Dr. Allen is an Independent Director at Verge Analytics, Inc. since 2021.
Dr. Allen is Director at Cullinan Therapeutics, Inc. starting 2025.
Dr. Allen is a Member of The Royal College of Physicians.
Former positions include Independent Director at Sierra Oncology, Inc. from 2017 to 2022; Director at Nodality, Inc.; Independent Director at Epizyme, Inc. from 2014 to 2021; Director at Cell Design Labs, Inc. from 2015 to 2017; Independent Director at TCR² Therapeutics, Inc. from 2018 to 2023; Independent Non-Executive Director at Adaptimmune Therapeutics Plc from 2023 to 2025; Head-Global Project at Abbott Laboratories from 2002 to 2004; Vice President-Oncology Drug Development at Chiron Corp.
from 2004 to 2006; Chief Medical Officer & Executive VP-Clinical at Pharmion Corp.
from 2006 to 2008; Principal at McKinsey & Co., Inc. from 1999 to 2002.
Education includes undergraduate studies at the University of Oxford and a doctorate from Imperial College London.